Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor-prognosis Hodgkin's disease

Peter H. Wiernik, Janice P. Dutcher, Avi Israel Einzig, Joseph A. Sparano, Martin Frank, William Friedenberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PURPOSE: A new regimen, MVC (mitoxantrone, vinblastine, and CCNU [lomustine]), was studied in advanced Hodgkin's disease. This regimen combines the most effective elements of previous regimens for poor-prognosis Hodgkin's disease and eliminates agents with unnecessary toxicities and marginal activity. Initially, patients with relapsed or refractory disease were entered, and after substantial activity was observed, patients with advanced-stage, newly diagnosed Hodgkin's disease were also treated. PATIENTS AND METHODS: Thirty-six relapsed or refractory patients were entered on this study. Prior treatment included radiotherapy alone (three patients), combined-modality treatment (n = 21), and single (n = 2) or multiple chemotherapy regimens (n = 10). Seventeen advanced-stage (bulky IIB-IVB) newly diagnosed Hodgkin's patients were also entered, with a median follow- up of 7 years. RESULTS: Thirty-two of 36 (88%) relapsed/refractory patients responded to MVC, with 18 partial responses (50%) and 14 complete responses (39%). Median complete response duration is 20 months (range, 2 to 108+ months). The median survival of all previously treated MVC patients is 28 months (range, 4 to 127+ months). Eleven of 32 previously treated MVC responders remain alive and disease-free at 12 to 127+ months, seven after autologous bone marrow transplantation (12 to 127+ months) and four after MVC without transplantation (31 to 113+ months). Thirteen of 17 advanced-stage, newly diagnosed Hodgkin's disease patients achieved a complete response and four achieved a partial response to MVC (100% response rate). Two complete response and all partial response patients have relapsed. Eight complete responses are ongoing at 11 to 114+ months. Three patients died in complete response at 11, 42, and 43 months. Median response duration has not been reached. DISCUSSION: MVC is a highly active regimen in relapsed and advanced- stage Hodgkin's disease, with outcome results comparable to other established regimens. Treatment is associated with myelosuppression but is otherwise well tolerated. MVC provides an effective alternative regimen for newly diagnosed patients with Hodgkin's disease and an effective salvage regimen for patients previously treated with anthracylines.

Original languageEnglish (US)
Pages (from-to)254-260
Number of pages7
JournalCancer Journal from Scientific American
Volume4
Issue number4
StatePublished - 1998

Fingerprint

Lomustine
Mitoxantrone
Vinblastine
Hodgkin Disease
Autologous Transplantation
Bone Marrow Transplantation

Keywords

  • Hogkin's disease
  • Mitoxantrone
  • Salvage therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC) : A highly active regimen for advanced and poor-prognosis Hodgkin's disease. / Wiernik, Peter H.; Dutcher, Janice P.; Einzig, Avi Israel; Sparano, Joseph A.; Frank, Martin; Friedenberg, William.

In: Cancer Journal from Scientific American, Vol. 4, No. 4, 1998, p. 254-260.

Research output: Contribution to journalArticle

@article{4a06f0cb91824549a6d7a0b36f869b93,
title = "Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor-prognosis Hodgkin's disease",
abstract = "PURPOSE: A new regimen, MVC (mitoxantrone, vinblastine, and CCNU [lomustine]), was studied in advanced Hodgkin's disease. This regimen combines the most effective elements of previous regimens for poor-prognosis Hodgkin's disease and eliminates agents with unnecessary toxicities and marginal activity. Initially, patients with relapsed or refractory disease were entered, and after substantial activity was observed, patients with advanced-stage, newly diagnosed Hodgkin's disease were also treated. PATIENTS AND METHODS: Thirty-six relapsed or refractory patients were entered on this study. Prior treatment included radiotherapy alone (three patients), combined-modality treatment (n = 21), and single (n = 2) or multiple chemotherapy regimens (n = 10). Seventeen advanced-stage (bulky IIB-IVB) newly diagnosed Hodgkin's patients were also entered, with a median follow- up of 7 years. RESULTS: Thirty-two of 36 (88{\%}) relapsed/refractory patients responded to MVC, with 18 partial responses (50{\%}) and 14 complete responses (39{\%}). Median complete response duration is 20 months (range, 2 to 108+ months). The median survival of all previously treated MVC patients is 28 months (range, 4 to 127+ months). Eleven of 32 previously treated MVC responders remain alive and disease-free at 12 to 127+ months, seven after autologous bone marrow transplantation (12 to 127+ months) and four after MVC without transplantation (31 to 113+ months). Thirteen of 17 advanced-stage, newly diagnosed Hodgkin's disease patients achieved a complete response and four achieved a partial response to MVC (100{\%} response rate). Two complete response and all partial response patients have relapsed. Eight complete responses are ongoing at 11 to 114+ months. Three patients died in complete response at 11, 42, and 43 months. Median response duration has not been reached. DISCUSSION: MVC is a highly active regimen in relapsed and advanced- stage Hodgkin's disease, with outcome results comparable to other established regimens. Treatment is associated with myelosuppression but is otherwise well tolerated. MVC provides an effective alternative regimen for newly diagnosed patients with Hodgkin's disease and an effective salvage regimen for patients previously treated with anthracylines.",
keywords = "Hogkin's disease, Mitoxantrone, Salvage therapy",
author = "Wiernik, {Peter H.} and Dutcher, {Janice P.} and Einzig, {Avi Israel} and Sparano, {Joseph A.} and Martin Frank and William Friedenberg",
year = "1998",
language = "English (US)",
volume = "4",
pages = "254--260",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC)

T2 - A highly active regimen for advanced and poor-prognosis Hodgkin's disease

AU - Wiernik, Peter H.

AU - Dutcher, Janice P.

AU - Einzig, Avi Israel

AU - Sparano, Joseph A.

AU - Frank, Martin

AU - Friedenberg, William

PY - 1998

Y1 - 1998

N2 - PURPOSE: A new regimen, MVC (mitoxantrone, vinblastine, and CCNU [lomustine]), was studied in advanced Hodgkin's disease. This regimen combines the most effective elements of previous regimens for poor-prognosis Hodgkin's disease and eliminates agents with unnecessary toxicities and marginal activity. Initially, patients with relapsed or refractory disease were entered, and after substantial activity was observed, patients with advanced-stage, newly diagnosed Hodgkin's disease were also treated. PATIENTS AND METHODS: Thirty-six relapsed or refractory patients were entered on this study. Prior treatment included radiotherapy alone (three patients), combined-modality treatment (n = 21), and single (n = 2) or multiple chemotherapy regimens (n = 10). Seventeen advanced-stage (bulky IIB-IVB) newly diagnosed Hodgkin's patients were also entered, with a median follow- up of 7 years. RESULTS: Thirty-two of 36 (88%) relapsed/refractory patients responded to MVC, with 18 partial responses (50%) and 14 complete responses (39%). Median complete response duration is 20 months (range, 2 to 108+ months). The median survival of all previously treated MVC patients is 28 months (range, 4 to 127+ months). Eleven of 32 previously treated MVC responders remain alive and disease-free at 12 to 127+ months, seven after autologous bone marrow transplantation (12 to 127+ months) and four after MVC without transplantation (31 to 113+ months). Thirteen of 17 advanced-stage, newly diagnosed Hodgkin's disease patients achieved a complete response and four achieved a partial response to MVC (100% response rate). Two complete response and all partial response patients have relapsed. Eight complete responses are ongoing at 11 to 114+ months. Three patients died in complete response at 11, 42, and 43 months. Median response duration has not been reached. DISCUSSION: MVC is a highly active regimen in relapsed and advanced- stage Hodgkin's disease, with outcome results comparable to other established regimens. Treatment is associated with myelosuppression but is otherwise well tolerated. MVC provides an effective alternative regimen for newly diagnosed patients with Hodgkin's disease and an effective salvage regimen for patients previously treated with anthracylines.

AB - PURPOSE: A new regimen, MVC (mitoxantrone, vinblastine, and CCNU [lomustine]), was studied in advanced Hodgkin's disease. This regimen combines the most effective elements of previous regimens for poor-prognosis Hodgkin's disease and eliminates agents with unnecessary toxicities and marginal activity. Initially, patients with relapsed or refractory disease were entered, and after substantial activity was observed, patients with advanced-stage, newly diagnosed Hodgkin's disease were also treated. PATIENTS AND METHODS: Thirty-six relapsed or refractory patients were entered on this study. Prior treatment included radiotherapy alone (three patients), combined-modality treatment (n = 21), and single (n = 2) or multiple chemotherapy regimens (n = 10). Seventeen advanced-stage (bulky IIB-IVB) newly diagnosed Hodgkin's patients were also entered, with a median follow- up of 7 years. RESULTS: Thirty-two of 36 (88%) relapsed/refractory patients responded to MVC, with 18 partial responses (50%) and 14 complete responses (39%). Median complete response duration is 20 months (range, 2 to 108+ months). The median survival of all previously treated MVC patients is 28 months (range, 4 to 127+ months). Eleven of 32 previously treated MVC responders remain alive and disease-free at 12 to 127+ months, seven after autologous bone marrow transplantation (12 to 127+ months) and four after MVC without transplantation (31 to 113+ months). Thirteen of 17 advanced-stage, newly diagnosed Hodgkin's disease patients achieved a complete response and four achieved a partial response to MVC (100% response rate). Two complete response and all partial response patients have relapsed. Eight complete responses are ongoing at 11 to 114+ months. Three patients died in complete response at 11, 42, and 43 months. Median response duration has not been reached. DISCUSSION: MVC is a highly active regimen in relapsed and advanced- stage Hodgkin's disease, with outcome results comparable to other established regimens. Treatment is associated with myelosuppression but is otherwise well tolerated. MVC provides an effective alternative regimen for newly diagnosed patients with Hodgkin's disease and an effective salvage regimen for patients previously treated with anthracylines.

KW - Hogkin's disease

KW - Mitoxantrone

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=0031903287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031903287&partnerID=8YFLogxK

M3 - Article

C2 - 9689984

AN - SCOPUS:0031903287

VL - 4

SP - 254

EP - 260

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 4

ER -